ImCheck Therapeutics: Valuation, Funding & Investors
ImCheck Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies that modulate innate immune checkpoints to treat cancer. The company advances antibody-based therapeutic programs designed to activate or reprogram innate immune cells and to be used alone or in combination with established oncology treatments. ImCheck also integrates translational biomarker strategies to inform patient selection and clinical development.
Leadership & Board
- Current Number of Employees
- 44
- Current LinkedIn Followers
- 11,853
Latest Estimated Valuation
- Total Amount Raised
- $22M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $22M
- Latest Funding Round
- Investment
Employee Trend
ImCheck Therapeutics had 44 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
ImCheck Therapeutics had 11,853 followers as of November 16, 2026. The number of followers increased by 4 (0.03%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 29, 2024 | Investment | $22.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| France 2030 | Investment |
Similar Companies
A snapshot of private companies similar to ImCheck Therapeutics, helping you discover and navigate related company profiles.







